Bye, bye blockbusters, hello niche busters

Collier, Roger
August 2011
CMAJ: Canadian Medical Association Journal;8/9/2011, Vol. 183 Issue 11, pE697
Academic Journal
The article presents suggestions on how pharmaceutical companies can re-drive their profits, when patents on blockbuster drugs expire across the world. It defines the concept of blockbuster philosophy, which has dominated the pharmaceutical industry and proposes that drugs should be developed for as many people as possible so as to achieve sales of at least one billion dollars. It highlights a parallel drug diagnostic model, which can increase the efficacy of pharmaceutical companies.


Related Articles

  • ACC Pearls.  // Formulary;May2001, Vol. 36 Issue 5, p367 

    Reports developments related to the drug industry in the United States as of May 2001. Effects of clopidogrel on patients with acute coronary syndrome; Effectiveness of rosuvastatin in reducing low-density lipoprotein cholesterol; Comparison of hospitalization costs between invasive and...

  • Neurochem: excitement builds as Alzhemed phase III trial is completed.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p19 

    The article reports on the completion of a phase III clinical trial by Neurochem Inc. for its Alzheimer's disease (AD) treatment Alzhemed. The phase III clinical trial has investigated the safety, efficacy and disease-modifying potential of Alzhemed for the treatment of mild-to-moderate AD...

  • Omnitarg (Breast Cancer) - Analysis and Forecasts to 2020.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article provides information on the report, Analysis and Forecast to 2020 by the company GlobalData. It states that the pharmaceutical report provide estimates for Omnitarg sales for the U.S and EU5. It reflects the report includes the clinical assessment of the drug, drug sales and sales...

  • Is pharmacogenomics a reality? Challenges and oppurtunities for India. Banerjee, Moinak // Indian Journal of Human Genetics;May-Aug2011 Supplement, Vol. 17, pS1 

    The author reflects on the challenges and opportunities that pharmacogenomics will brought to India. He states that even though India has the 20% of the world population, their pharmaceutical market is only two percent of the global market. The author says that most of the pharmaceutical...

  • Vantage Point. McDonald, Susan Schwartz // Medical Marketing & Media;Feb2012, Vol. 47 Issue 2, p25 

    The article reports on a survey conducted to 156 leaders in the U.S. and Europe which reveals that 68% of respondents believed that the commercial pharmaceutical model is broken.

  • Local pharmaceutical drug sales reached $769 million in FY 2000, a 30% hike. Martinez, Marialba // Caribbean Business;11/23/2000, Vol. 28 Issue 46, p4 

    Reports the local pharmaceutical drug sales for the fiscal year 2000 in Puerto Rico. Cost estimates in the development of innovative drugs; Impact of existing tax incentives for research and development technology on pharmaceutical companies; Accounts of the Pharmaceutical Industry Association...

  • Pharmaceutical companies show 3Q gains. Martinez, Marialba // Caribbean Business;11/23/2000, Vol. 28 Issue 46, p14 

    Forecasts the earning growth in the pharmaceutical industry for fourth quarter of 2000 in Puerto Rico. Account on companies with the highest rating given by Multex Investor analysts; Selection of Cardinal Health as the most financially attractive firm in the industry; Names of companies with...

  • Reaching Your Customers Where They Live. Shababb, George // Medical Marketing & Media;Oct98, Vol. 33 Issue 10, p112 

    Discusses the effectiveness of using direct-to-customer services in the United States pharmaceutical industry. How the service can be enhanced; Marketing techniques used by companies; Factors which should be considered by manufacturers when spending money in mass mailings, co-marketing and...

  • GROUP SELLING TECHNIQUES AT CONVENTIONS PAY OFF. Konopacki, Allen // Medical Marketing & Media;May2000, Vol. 35 Issue 5, p110 

    Focuses on the benefits of United States-based pharmaceutical companies' practice of group selling techniques during medical conventions. High costs associated with one-to-one selling; Creation of consultative interactions with four to six physicians at a time; Reduction of representatives'...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics